PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Bio-Rad Laboratories, Inc. (BIO)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS0905722072
CUSIP090572207
SectorHealthcare
IndustryMedical Devices

Highlights

Market Cap$9.05B
EPS (TTM)-$47.34
PEG Ratio1.19
Total Revenue (TTM)$2.56B
Gross Profit (TTM)$1.38B
EBITDA (TTM)$546.21M
Year Range$261.59 - $384.37
Target Price$366.00
Short %5.46%
Short Ratio4.04

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Bio-Rad Laboratories, Inc.

Popular comparisons: BIO vs. TMO, BIO vs. SPY, BIO vs. VOO

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Bio-Rad Laboratories, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-25.00%-20.00%-15.00%-10.00%-5.00%0.00%5.00%10.00%AprilMayJuneJulyAugustSeptember
-5.12%
7.53%
BIO (Bio-Rad Laboratories, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Bio-Rad Laboratories, Inc. had a return of -1.14% year-to-date (YTD) and -11.81% in the last 12 months. Over the past 10 years, Bio-Rad Laboratories, Inc. had an annualized return of 10.50%, which was very close to the S&P 500 benchmark's annualized return of 10.86%.


PeriodReturnBenchmark
Year-To-Date-1.14%16.44%
1 month0.25%3.92%
6 months-5.12%7.53%
1 year-11.81%24.48%
5 years (annualized)-0.93%13.10%
10 years (annualized)10.50%10.86%

Monthly Returns

The table below presents the monthly returns of BIO, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-0.62%1.56%6.13%-22.01%6.34%-4.79%23.89%-0.31%-1.14%
202311.17%2.22%0.25%-5.89%-17.18%1.55%6.92%-1.27%-10.43%-23.20%10.77%5.89%-23.21%
2022-20.63%4.37%-10.02%-9.09%5.02%-7.96%13.79%-13.89%-14.00%-15.69%17.91%1.39%-44.35%
2021-1.57%1.87%-2.28%10.32%-4.41%6.96%14.78%8.83%-7.31%6.53%-5.22%0.31%29.61%
2020-2.46%-2.47%-0.41%25.54%11.64%-8.11%16.26%-3.11%1.35%13.77%-8.17%8.25%57.54%
20197.60%8.42%12.84%-1.55%-4.65%8.94%0.74%7.24%-1.47%-0.34%11.39%0.18%59.34%
20188.32%4.45%-7.39%1.45%13.17%0.49%6.28%6.08%-3.78%-12.82%0.59%-15.39%-2.70%
20174.28%2.40%2.41%9.49%2.39%1.27%4.12%-7.56%2.02%-1.09%23.44%-12.03%30.94%
2016-7.97%5.51%1.54%3.75%4.93%-3.92%1.45%2.56%10.08%-3.50%9.75%5.06%31.46%
2015-5.05%11.10%6.29%-0.54%7.38%4.32%0.09%-7.57%-3.60%3.85%0.17%-0.76%15.01%
20142.84%2.05%-1.23%-3.83%-2.01%-0.84%-3.94%4.58%-5.70%-0.51%5.29%1.49%-2.47%
20138.32%8.27%2.27%-4.96%-5.07%-1.30%8.73%-6.54%3.11%5.07%-0.73%0.81%17.67%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of BIO is 31, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.


The Risk-Adjusted Performance Rank of BIO is 3131
BIO (Bio-Rad Laboratories, Inc.)
The Sharpe Ratio Rank of BIO is 2929Sharpe Ratio Rank
The Sortino Ratio Rank of BIO is 2626Sortino Ratio Rank
The Omega Ratio Rank of BIO is 2727Omega Ratio Rank
The Calmar Ratio Rank of BIO is 3838Calmar Ratio Rank
The Martin Ratio Rank of BIO is 3636Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Bio-Rad Laboratories, Inc. (BIO) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


BIO
Sharpe ratio
The chart of Sharpe ratio for BIO, currently valued at -0.38, compared to the broader market-4.00-2.000.002.00-0.38
Sortino ratio
The chart of Sortino ratio for BIO, currently valued at -0.34, compared to the broader market-6.00-4.00-2.000.002.004.00-0.34
Omega ratio
The chart of Omega ratio for BIO, currently valued at 0.96, compared to the broader market0.501.001.502.000.96
Calmar ratio
The chart of Calmar ratio for BIO, currently valued at -0.18, compared to the broader market0.001.002.003.004.005.00-0.18
Martin ratio
The chart of Martin ratio for BIO, currently valued at -0.68, compared to the broader market-5.000.005.0010.0015.0020.00-0.68
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.86, compared to the broader market-4.00-2.000.002.001.86
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.53, compared to the broader market-6.00-4.00-2.000.002.004.002.53
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.33, compared to the broader market0.501.001.502.001.33
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.68, compared to the broader market0.001.002.003.004.005.001.68
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 8.89, compared to the broader market-5.000.005.0010.0015.0020.008.89

Sharpe Ratio

The current Bio-Rad Laboratories, Inc. Sharpe ratio is -0.38. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Bio-Rad Laboratories, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00AprilMayJuneJulyAugustSeptember
-0.38
1.86
BIO (Bio-Rad Laboratories, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Bio-Rad Laboratories, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-70.00%-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%AprilMayJuneJulyAugustSeptember
-61.35%
-2.00%
BIO (Bio-Rad Laboratories, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Bio-Rad Laboratories, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Bio-Rad Laboratories, Inc. was 76.26%, occurring on Aug 19, 1982. Recovery took 717 trading sessions.

The current Bio-Rad Laboratories, Inc. drawdown is 61.35%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-76.26%Jan 26, 1981397Aug 19, 1982717Jun 19, 19851114
-68.75%Feb 17, 19871740Dec 31, 1993343May 11, 19952083
-68.03%Sep 3, 2021709Jul 1, 2024
-50.88%Aug 12, 2008144Mar 9, 2009277Apr 14, 2010421
-48.46%Jul 5, 1996666Feb 24, 1999484Jan 24, 20011150

Volatility

Volatility Chart

The current Bio-Rad Laboratories, Inc. volatility is 7.21%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%12.00%AprilMayJuneJulyAugustSeptember
7.21%
4.58%
BIO (Bio-Rad Laboratories, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Bio-Rad Laboratories, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Bio-Rad Laboratories, Inc..


Loading data...

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items